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During the acute phase of HIV infection, a 
rapid immune response is required to counter-
act viral replication (Deeks and Walker, 2007). 
The innate immune system senses pathogens 
through PRRs (pattern-recognition receptors) 
and triggers the activation of antimicrobial de-
fenses. PRR stimulation leads to the secretion 
of cytokines, e.g., IFNs, which increase the ex-
pression of intrinsic factors such as APOBEC3G   
(A3G),  thus  preventing  viral  replication  and 
spread (Peng et al., 2006).
A3G belongs to the activation-induced de-
aminase (AID)/apolipoprotein B editing com-
plex (APOBEC) family of cytidine deaminases. 
AID has important functions in adaptive immu-
nity including B cell receptor editing and class 
switching (Rosenberg and Papavasiliou, 2007). 
The APOBEC3-A, -B, -H, -G, and -F deami-
nases inhibit the replication of a wide range of 
viruses such as HIV and endogenous retroviruses 
(Esnault et al., 2005; Goila-Gaur and Strebel, 
2008; Vartanian et al., 2008). A3G expression in 
lymphocytes, macrophages, and DCs is regulated 
by cytokines such as IFN- and IL-2 (Koning   
et al., 2009). A3G restricts HIV replication via at 
least two mechanisms. First, A3G is packaged 
into newly formed HIV particles and subse-
quently edits dC residues to dU in the nascent 
proviral minus strand (Harris et al., 2003; Mangeat 
et al., 2003; Zhang et al., 2003). A3G-mediated 
editing is very efficient, with up to 20% of all 
minus strand dC residues being deaminated to 
dU, which ultimately results in incorporation of 
A residues in the plus strand and subsequent G-
to-A hypermutations in the proviral genome. A 
large part of edited proviruses will be defective. 
Second, in resting CD4+ T cells, cellular A3G 
might  act  as  a  postentry  antiviral  factor  via   
its RNA-binding properties rather than by its   
deaminase activity (Chiu et al., 2005). However, 
this issue is controversial (Kamata et al., 2009).
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The cytidine deaminase APOBEC3G (A3G) enzyme exerts an intrinsic anti–human immunode-
ficiency virus (HIV) defense by introducing lethal G-to-A hypermutations in the viral genome. 
The HIV-1 viral infectivity factor (Vif) protein triggers degradation of A3G and counteracts 
this antiviral effect. The impact of A3G on the adaptive cellular immune response has not 
been characterized. We examined whether A3G-edited defective viruses, which are known  
to express truncated or misfolded viral proteins, activate HIV-1–specific (HS) CD8+ cytotoxic  
T lymphocytes (CTLs). To this end, we compared the immunogenicity of cells infected with 
wild-type or Vif-deleted viruses in the presence or absence of the cytidine deaminase. The 
inhibitory effect of A3G on HIV replication was associated with a strong activation of  
cocultivated HS-CTLs. CTL activation was particularly marked with Vif-deleted HIV and with 
viruses harboring A3G. Enzymatically inactive A3G mutants failed to enhance CTL activation. 
We also engineered proviruses bearing premature stop codons in their genome as scars of 
A3G editing. These viruses were not infectious but potently activated HS-CTLs. Therefore,  
the pool of defective viruses generated by A3G represents an underestimated source of viral 
antigens. Our results reveal a novel function for A3G, acting not only as an intrinsic antiviral 
factor but also as an inducer of the adaptive immune system.
© 2010 Casartelli et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.jem.org/misc/terms.shtml). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS AND DISCUSSION
Vif-deficient HIV-1 is a potent activator of HS-CTLs
We first analyzed how T cells infected with WT or vif HIV 
stimulate HS-CTLs. To this end, primary CD4+ T cells 
harboring endogenous A3G were infected with HIV particles 
produced in the absence of A3G (Fig. 1 A). From the litera-
ture, we anticipated that after CD4+ T infection, A3G will be 
incorporated in the progeny virions, thus exerting its editing 
activity starting from the second cycle of replication. Viral 
propagation was monitored by flow cytometry (intracellular 
Gag staining; Fig. 1 B). As expected, replication of HIV∆vif 
was markedly reduced compared with HIV, with 3 and 20% 
Gag+ cells at day 5 after infection, respectively. We compared 
the ability of HIV and HIV∆vif-infected CD4+ T cells to acti-
vate EM40-F21, an HS CD8+ CTL clone (Fig. 1 C). EM40-
F21 was derived from an HIV-infected patient and recognizes 
a well-characterized immunodominant epitope of Gag p17 
(SL9)  presented  by  HLA-A*0201  (Moris  et  al.,  2004).   
Surprisingly, HIV∆vif-infected CD4+ T cells activated EM40-
F21 to a greater extent than cells infected with the WT virus 
(Fig. 1 C). Similar results were obtained with cells from three 
different donors infected with various HIV inocula (Fig. 1 D). 
When expressed as the number of IFN-–producing CTL/
Gag+ CD4 cells, CD4+ T cells infected with HIV∆vif were 
found to be two to three times more efficient at activating 
HS-CTLs than HIV-infected cells (Wilcoxon rank-sum test: 
P = 0.032; Fig. 1 D). These data strongly suggest that there is 
dissociation between the capacity of HIV∆vif to infect CD4+ 
T cells and to activate HS-CTLs.
To escape CTL recognition, the HIV Nef protein down-
regulates the surface expression of HLA class I molecules 
(Schwartz et al., 1996). We asked whether Nef might affect 
the immunogenicity of HIV∆vif-infected T cells. To this end, 
we constructed a ∆nef∆vif double mutant (HIV∆nefvif). HIV∆nef 
isolates replicate less efficiently than WT virus. To obtain suf-
ficient numbers of infected cells, CD4+ T lymphocytes were 
exposed  to  VSV-G–pseudotyped  HIV∆nef  and  HIV∆nefvif  
(Fig. 1 E). HIV∆nefvif replication was reduced (three- to sixfold) 
compared with HIV∆nef at 48 and 72 h after infection. Remark-
ably, at each time point, even if very few Gag+ cells were   
detected, HIV∆nefvif induced a robust activation of HS-CTLs 
(Fig. 1 F). As expected, Nef-deficient isolates were more   
efficient than WT virus in activating CTLs (Fig. 1, compare 
C and F). Similar results were obtained with cells from eight 
different donors (Fig. 1 G), demonstrating that cells infected 
with HIV∆nefvif were two to three times more efficient than 
HIV∆nef-infected cells in activating HS-CTLs (Wilcoxon 
rank-sum test: P = 0.0005; Fig. 1 G). Therefore, the enhancing 
effect of ∆vif on CTL activation is observed both in the con-
text of WT and ∆nef HIV.
CTLs secrete a panel of chemokine and cytokine upon 
activation (Price et al., 1998; Wagner et al., 1998; Appay   
et al., 2008). We performed a peptide titration experiment to 
identify cytokines other than IFN- that are secreted in an 
antigen-specific  manner  by  EM40-F21.  Primary  CD4+  
T cells were loaded with the SL9 peptide, co-cultured with 
The viral infectivity factor (Vif) from HIV-1 counteracts 
this  deaminase-dependent  inhibition  of  viral  replication   
but has less effect on the RNA-binding block mediated by 
A3G. In infected cells, Vif targets A3G for proteasomal deg-
radation, thus reducing the amount of A3G incorporated 
into the virions as well as the efficiency of viral RNA edit-
ing in the target cells (Mariani et al., 2003; Yu et al., 2003). 
In vivo, the action of Vif is not absolute and hypermutated 
viral genomes have been isolated from the PBMCs of HIV-
1–positive individuals at different stages of infection (Kieffer 
et al., 2005; Kijak et al., 2008). Editing patterns are dominated 
by GG-to-AG hypermutations, leading to a high frequency 
of  amino  acid  substitutions  and  to  the  introduction  of   
premature STOP codons (Vartanian et al., 1991). These 
crippled proviruses express aberrant (misfolded/truncated) 
viral proteins and are unable to produce infectious particles   
(Simm et al., 1995).
Viral recognition by the innate immune system activates 
the adaptive immune response. HIV-1–specific (HS) CD8+ 
CTLs are involved in the decrease of viremia during acute 
infection and chronic stages of the disease (Goulder and 
Watkins, 2008). CTLs freshly isolated from the blood of   
infected individuals inhibit HIV-1 replication in autologous 
CD4+ T cells (Sáez-Cirión et al., 2007). Despite the pres-
ence  of  CTLs,  most  infected  individuals  control  viremia 
poorly in the absence of antiviral treatment. Several cellular 
and viral factors contribute to the failure of the immune   
system to control HIV-1 (Deeks and Walker, 2007). The 
emerging concept is that the quality, rather than the magni-
tude, of T cell response is crucial for determining disease 
outcome of various infections, including HIV (Appay et al., 
2008). Our understanding of CD8+ T cell efficacy in HIV-1 
infection  is  limited.  Multiple  factors,  including  antigen   
processing and presentation by infected cells, contribute to   
the activation of effective T cell responses. CTLs recognize 
peptides  derived  from  exogenous  or  endogenous  sources 
and presented by MHC class I (MHC-I) molecules. Most 
endogenous peptides loaded onto MHC-I molecules are   
derived from nascent polypeptides. These polypeptides orig-
inate primarily from errors during transcription, translation, 
and/or folding and are degraded by the proteasome (Yewdell 
and Nicchitta, 2006).
In this paper, we examined the role of A3G in the gener-
ation of MHC-I–restricted HIV antigens. We first studied 
the immunogenicity of WT and mutant HIV isolates (e.g., 
HIV∆vif). We then analyzed the role of A3G editing in HS-
CTL activation. Finally, we engineered defective viruses   
expressing truncated Gag proteins that induced a robust acti-
vation of HS-CTLs by mimicking A3G editing. Altogether, 
our results uncover a dissociation of the capacity of A3G-edited 
viruses to productively infect cells and to activate HS-CTL 
responses. We demonstrate that A3G editing enhances the 
ability of HIV-infected cells to activate HS-CTLs. Therefore, 
A3G cytidine deaminase not only acts as an intrinsic antiviral 
factor but also regulates the recognition of HIV-infected cells 
by the immune system.JEM VOL. 207, January 18, 2010  41
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(Fig. 2, B and C). We then measured in co-culture superna-
tants the release of MIP-1 and MIP-1. Upon co-culture 
with HIV∆nef- and HIV∆nefvif-infected targets (at a ratio of 1 
CTL to 50 CD4+ target cells), EM40-F21 secreted similar 
levels of MIP-1 (130 and 106 pg/ml, respectively; Fig. 2 D). 
HIV∆nef- and HIV∆nefvif-infected cells also allowed the secre-
tion of MIP-1 (292 and 167 pg/ml, respectively; Fig. 2 G). 
These levels were at least three times higher than background 
secretion induced by uninfected control cells (Fig. 2, D and 
G). HIV infection did not increase the background lympho-
kine production by target CD4+ T cells alone (unpublished 
HS-CTLs, and lymphokine production was analyzed in   
culture supernatants using the luminex technology. As previ-
ously reported (Price et al., 1998; Wagner et al., 1998), we 
observed a dose-dependent secretion of MIP-1 and MIP-
1 (Fig. 2, F and I). Thereafter, we examined the effect of 
∆vif viruses on MIP-1 and MIP-1 secretions by EM40-
F21. Primary T cells were infected with VSV-G-HIV∆nef and 
-HIV∆nefvif, monitored for Gag expression (12 and 1% of Gag+ 
cells, respectively), and used to activate EM40-F21 (Fig. 2, A, 
B, D, and G). Using IFN- Elispot, we first confirmed the 
enhancing effect of ∆vif on IFN- secretion by EM40-F21 
Figure 1.  Vif-deficient HIV-1 is a potent activator of HS-CTLs. (A) Viruses were produced by transfection of 293T cells (that do not express  
endogenous A3G). Viruses were then used to infect PHA-activated primary CD4+ T cells. Endogenous A3G (red) is incorporated into the progeny virions 
and exerts its editing activity starting from the second cycle of replication. (B) Activated T cells were incubated with HIVNL or HIVNL∆vif (100 ng/ml p24) and 
the kinetic of viral infection analyzed by intracellular Gagp24 FACS staining. (C) At day 5 after infection, infected cells were collected and used to stimu-
late HS-CTL clone EM40-F21 (2,500 clone/well) in an IFN- Elispot. Background IFN- production induced by uninfected cells is shown. Background IFN- 
productions by target cells alone have been subtracted and are at least three times lower than with HS-CTLs. Activation levels reached using SL9 peptide–
loaded cells as positive control were 600 IFN-+ spots/well (not depicted). Data are mean (±SD) of triplicates. (D) Data from six experiments performed 
as in B and C, using primary CD4+ cells from three donors, are presented as IFN-+ spots to percentage of Gag+ cells (as measured by FACS) on a logarith-
mic scale. CD4+ T cells infected with Vif-deficient HIV-1 are more efficient than WT HIV-infected cells in activating HS-CTL (P = 0.032, Wilcoxon rank-sum 
test). Each symbol corresponds to an independent experiment. Horizontal bars indicate the mean IFN-/Gag+ cell ratio based on six experiments. (E) Acti-
vated primary CD4+ T cells were incubated with VSV-pseudotyped HIVNL∆nef or HIVNL∆nefvif and kinetic of viral infection monitored (as in A). (F) Infected  
cells were collected and used to stimulate EM40-F21 (as in C). Data are the mean (±SD) of triplicates. (G) Similar results were obtained with cells from 
eight donors infected at various inocula. Data are presented as IFN-+ spots to percentage of Gag+ cells on a logarithmic scale. CD4+ T cells infected  
with Vif-deficient HIV∆nef are more efficient than HIV∆nef-infected cells in activating HS-CTLs (P < 0.0005, Wilcoxon rank-sum test). Horizontal bars  
indicate the mean IFN-/Gag+ cell ratio. NI, noninfected cells; p.i., post infection.42 APOBEC3G promotes CTL activation | Casartelli et al.
with HIV∆nefvif viruses likely present four to six times more 
peptide antigen than cells infected with HIV∆nef. This calcu-
lation was done using populations harboring different per-
centages of Gag+ cells. It would have also been informative 
to confirm these findings by calculating exogenous peptide 
equivalents in the presence of equal number of infected 
(Gag+) target cells. The low replicative capacity of HIV∆nefvif 
in primary CD4+ T cells precluded this possibility. As ex-
pected, titrating down the amount of infected cells in the 
co-culture (1 CTL for 10 CD4+ targets) reduced the overall 
secretion levels and confirmed that in the absence of Vif, in-
fected cells enhance cytokine production by HS-CTLs (Fig. S1). 
It  is  noteworthy  that  Nevirapine,  a  reverse  transcription   
inhibitor of viral replication, blocked antigen presentation, 
indicating that activation of EM40-F21 was not a result of 
the presentation of incoming HIV antigens (Fig. 2, A and B). 
data). We noticed that the secretion of MIP-1 with ∆nefvif 
viruses was reduced as compared with ∆nef (Fig. 2 G), sug-
gesting that the effect of ∆vif viruses might vary depending on 
the lymphokine. Nonetheless, even if very few Gag+ cells 
were detected, HIV∆nefvif induced a potent secretion of both 
MIP-1 and MIP-1 by HS-CTLs (Fig. 2, E and H). To 
gain information on the magnitude of A3G-mediated effect, 
we used MIP-1 and MIP-1 SL9 peptide titration curves 
(Fig. 2, F and I) as standards to calculate the relative antigen 
presentation levels on the surface of infected (Gag+) target 
cells. Based on MIP-1 secretion, HIV∆nef- and HIV∆nefvif-
infected cells presented 6.6 × 1015 and 4 × 1014 exogenous 
peptide equivalent, respectively. Based on MIP-1 secretion, 
the relative antigen presentation levels were 1.98 × 1015 and 
7.9 × 1015 exogenous peptide equivalent for HIV∆nef- and 
HIV∆nefvif Gag+ cells, respectively. Thereafter, cells infected 
Figure 2.  Vif-deficient HIV-1 stimulates chemokine secretion of HS-CTLs. (A) Activated primary CD4+ T cells were incubated with VSV-pseudotyped 
HIVNL∆nef or HIVNL∆nefvif in the presence or absence of Nevirapine (NVP). At day 4 after infection, viral replication was monitored by FACS. The percentage  
of infected (Gag+) cells is indicated. (B) Infected cells were then used to stimulate HS-CTL clone EM40-F21 in an IFN- Elispot (2,500 clones/well). Activa-
tion levels reached, using SL9 peptide–loaded cells as positive control, were 600 IFN-+ spots/well (not depicted). Data are the mean (±SD) of triplicates 
and are representative of at least three independent experiments. (C) IFN- Elispot data are presented as IFN-+ spots to percentage of Gag+ cells.  
(D and G) 2.5 × 105 HIVNL∆nef- and HIVNL∆nefvif-infected cells were co-cultured for 24 h with 5 × 103 EM40-F21 (50/1 ratio). Culture supernatants were collected 
and the release of the indicated chemokine quantified by Luminex. Background secretions in the absence of HS-CTLs have been subtracted. HIV infection 
didn’t induce an increase of the background lymphokine productions by target CD4+ T cell alone (not depicted). (E and H) Chemokine quantifications  
presented as concentration to percentage of Gag+ cells. (F and I) Activated T cells were loaded with SL9 peptide at the indicated concentrations,  
co-cultured for 24 h with EM40-F21 (50/1 ratio), and chemokine release was measured by Luminex. Luminex data are the mean (±SD) of duplicates  
and are representative of three independent experiments.JEM VOL. 207, January 18, 2010  43
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Collectively, our results demonstrate that Vif-deficient HIV-1 
replicates less efficiently but is a potent activator of HS-CTLs, 
inducing the secretion of various lymphokines such as IFN-, 
MIP-1, and MIP-1. More specifically, Vif impacts the 
immunogenicity of HIV-infected T cells. In infected cells, Vif 
targets A3G for proteasomal degradation (Mariani et al., 2003; 
Yu et al., 2003); therefore, A3G may render HIV-infected 
cells more able to activate CTLs.
A3G-mediated viral restriction enhances HS-CTL activation
We further analyzed the contribution of A3G restriction in 
HS-CTL activation. We examined the effect of A3G, incor-
porated  into  incoming  virions,  on  viral  replication.  Viral   
particles were produced in the presence or absence of A3G 
(Fig. 3 A; and Fig. S2, B and C; Gaddis et al., 2003). A3G 
expression was confirmed by Western blotting (Fig. S2 C). 
As expected, the amount of A3G was markedly reduced with 
Vif+ viruses (Fig. S2 C). In an assay of a single cycle of repli-
cation, A3G moderately reduced the infectivity of WT or 
HIV∆nef, whereas HIV∆vif isolates were highly sensitive to A3G 
inhibition (Fig. S2 B).
CEM-A2, a CD4+ T cell line which does not express   
endogenous A3G (Gaddis et al., 2003), was infected with 
HIV∆nef, produced in the presence (HIV∆nef + A3G) or absence 
of A3G (Fig. 3 A). The use of HIV∆nef enables better CTL   
activation (Fig. 1). We did not use a ∆vif HIV in this setting 
because this mutant was not viable when produced with A3G 
(Fig. S2 B). Importantly, in this experimental system, A3G 
exerts its editing activity exclusively on the first cycle of   
infection (Fig. 3 A). An infection peak was reached 2 d after 
HIV∆nef- and HIV∆nef + A3G infection with 78 and 26% Gag+ 
cells, respectively, thus confirming that A3G generates partly 
defective viruses (Fig. 3 B). Remarkably, HIV∆nef + A3G–
infected cells induced a robust activation of the CTL clone 
EM40-F21 (Fig. 3 C). Similar data were obtained with two 
different HIV isolates (NL4-3 and SF2) used at various inoc-
ula (Fig. 3 D). Notably, when expressed as the number of 
IFN-–producing CTL/Gag+ CD4 T cells, HIV∆nef + A3G–
infected cells were two to three times more efficient in acti-
vating  HS-CTLs  than  HIV∆nef-infected  cells  (Wilcoxon 
rank-sum test: P = 0.0005; Fig. 3 D). To further highlight 
the role of A3G in enhancing CTL activation, we compared 
the capacity of CEM-A2 with similar levels of Gag+ cells to 
activate HS-CTLs. Data from six independent experiments 
are presented in Fig. 3 (E and F). In the presence of A3G, 
there  was  a  stronger  activation  of  EM40-F21  (Wilcoxon 
rank-sum test: P = 0.015; Fig. 3 F).
The CTL clone EM40-F21 is specific for a Gag-derived 
epitope presented by HLA-A2. We examined whether A3G 
also activates CTLs that recognize other viral epitopes. To this 
end,  we  generated  a  Nef-specific  CTL  line,  restricted  by 
HLA-B*07.  As  a  negative  control,  we  used  CTLs  raised 
against a CMV epitope. An HLA-B*07+ cell line, T1-B7, was 
used as target (Cardinaud et al., 2004). T1-B7 cells were   
infected with HIV or HIV + A3G. At 24 h after infection, 
cells were monitored for viral replication and used as targets in 
Elispot assays. As expected, replication of HIV + A3G was 
reduced compared with HIV alone (unpublished data). CMV-
specific control T cells did not react with HIV-infected cells 
(Fig. 3 H). T1-B7 cells infected with HIV + A3G induced a 
strong activation of Nef-specific CTLs (Fig. 3 G). Activation 
with HIV + A3G–infected cells was threefold higher than 
with HIV-infected cells (Fig. 3 G). When normalized to the 
amount of infected (Gag+) cells, HIV + A3G–infected cells 
activated Nef-specific CTLs ninefold better than HIV-infected 
cells (unpublished data). Overall, using two HIV isolates 
(NL4-3 and SF2) and CTLs specific for two different HIV 
proteins (Gag and Nef) presented by distinct HLA molecules 
(HLA-A2 and -B7), we demonstrated that A3G enhances rec-
ognition of HIV-infected cells by HS-CTLs.
The editing activity of A3G is required to promote  
HS-CTL activation
We then questioned whether the editing activity of A3G is 
necessary to promote HS-CTL stimulation. A3G possesses two 
consensus deaminase motifs, which is a hallmark of APOBEC 
protein family members. Mutations in the C-terminal deami-
nase motif (such as H257R and C288S) abrogate editing   
activity (Haché et al., 2005; Newman et al., 2005).
HIV∆nef particles were produced in the presence of WT 
or mutant (H257R and C288S) A3G. The amounts of WT 
and mutant A3G proteins were comparable (Fig. S2 C). 
CEM-A2+ cells were infected with two different doses of 
virus (Fig. 4 A). At 48 h after infection, the percentage of 
infected cells was reduced using HIV∆nef + A3G compared 
with HIV∆nef, whereas HIV∆nef produced in the presence of 
A3G mutants H257R and C288S replicated to levels similar 
to those of HIV∆nef. Infected cells were then used to stimulate 
HS-CTL EM40-F21 (Fig. 4 B). As already observed, cells 
infected with HIV∆nef + A3G activated HS-CTLs to a great 
extent, which was comparable to activation levels obtained 
with HIV∆nef-infected cells. Cells infected with HIV∆nef con-
taining A3G mutants also induced strong IFN- secretion 
(Fig. 4 B). When expressed as IFN-+ CTLs/Gag+ CD4 
cells, HIV∆nef + A3G was twofold more efficient in activating   
HS-CTL than HIV∆nef. Mutating the deaminase motif of 
A3G abrogated the capacity of A3G to enhance CTL activation   
(Fig. 4 C). Similar results were also obtained using another 
A3G  mutant  lacking  both  N-  and  C-terminal  cytosine   
deaminase motifs (H65R/H257R; unpublished data). Thus, 
the editing activity of A3G is required to mediate its effect on 
HS-CTL-recognition.
Defective viruses with premature STOP codons are 
efficiently recognized by HS-CTLs
In HIV samples derived from patients, editing patterns are 
dominated by GG-to-AG hypermutations (Vartanian et al., 
1991). On the protein level, this preferential editing leads to 
a high proportion of tryptophan (TGG) to STOP codon   
(e.g., TAG) substitutions.
We asked whether the expression of aberrant HIV pro-
teins with premature STOP codons might be involved in the 44 APOBEC3G promotes CTL activation | Casartelli et al.
Figure 3.  A3G-mediated viral restriction enhances HS-CTL activation. (A) Viruses were produced upon cotransfection in 293T cells of HIV genome 
and plasmids encoding for A3G. CEM-A2+ cells were then infected. CEM-A2+ cells do not express A3G (blue); hence, exogenous A3G exerts its editing 
activity exclusively during the first cycle of replication. (B) CEM-A2+ cells were incubated with HIVSF2∆nef or HIVSF2∆nef + A3G (100 ng/ml p24) and the ki-
netic of viral infection analyzed by p24 FACS staining. (C) 48 h after infection, infected cells were collected and used to stimulate HS-CTL clone EM40-F21 
in an IFN- Elispot (10,000 clones/well). Background IFN- production induced by uninfected cells is shown. Background IFN- productions by CEM-A2+ 
cells alone were close to zero. Activation levels with SL9 peptide–loaded cells were around 600 IFN-+ spots/well (not depicted). Data are the mean (±SD) 
of triplicates. (D) Data from nine independent experiments performed as in B and C using two HIV isolates (NL∆nef and SF2∆nef) are presented as IFN-+ 
spots to percentage of Gag+ cells on a logarithmic scale. CEM-A2+ cells infected with HIV∆nef + A3G are more efficient than HIV∆nef-infected cells in acti-
vating HS-CTL (P < 0.0005, Wilcoxon rank-sum test). Each symbol corresponds to an independent experiment. Horizontal bars indicate the mean IFN-/
gag+ cell ratio based on the nine independent experiments. (E) To reach similar numbers of Gag+ cells, CEM-A2+ cells were infected with 5–10× more 
HIVSF2∆nef + A3G than HIVSF2∆nef (doses ranging from 20 to 100 ng p24/ml). The percentage of Gag+ cells achieved at 48 h after infection is indicated for six 
independent experiments. Using these experimental conditions, there is no difference in terms of gag+ cells between HIVSF2∆nef or HIVSF2∆nef + A3G-infected 
cells (P = 0.29, Wilcoxon rank-sum test). Horizontal bars indicate the mean percentage of Gag+ cells based on the six independent experiments. (F) In-
fected cells were then used in Elispot assays to stimulate EM40-F21 (10,000 clones/well). Results of six independent experiments are summarized. In the 
presence of A3G, there was a stronger CTL activation (P = 0.015, Wilcoxon rank-sum test). Each symbol in E and F corresponds to an independent experi-
ment. Horizontal bars indicate the mean IFN- Elispot response based on the six independent experiments. (G) T1-B7 cells were incubated with HIVSF2 or 
HIVSF2 + A3G (100 ng/ml p24). 48 h after infection, cells were submitted to an IFN- Elispot assay to activate HIV Nef-specific CTLs restricted by HLA-
B*0702 (104 CTL/well). HIV Nef-specific CTL lines were generated in three different HLA-B*0702 transgenic mice and used in two independent experiments. 
One representative experiment with one CTL line is shown. (H) As in F, HIV-infected cells were used to activate a control CTL line specific for CMV. Data are 
the mean (±SD) of triplicates.JEM VOL. 207, January 18, 2010  45
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enhanced immunogenicity mediated by A3G. Downstream 
of the Gagp17 epitope SL9 recognized by EM40-F21, we 
identified two tryptophan codons (W212 and W249) that are 
potential targets for A3G editing. HIV proviruses with STOP 
codons at these positions have been previously isolated from 
PBMCs of infected individuals (Kijak et al., 2008). In addi-
tion, A3G edits these tryptophans into STOP codons in vitro 
(Armitage et al., 2008). We thus mimicked A3G editing by 
introducing STOP codons at these two positions, yielding 
HIV∆nefP2-Stop  and  HIV∆nefP3-Stop,  respectively.  Upon 
transfection, HIV∆nefP2 and HIV∆nefP3 led to the expression of 
truncated Gag proteins of 24 and 34 kD, respectively (Fig. 5 B). 
Viral particles produced were not infectious (not depicted) 
and lacked Gag p24 expression (Fig. 5 C). Transfected HeLa-
HLA-A2+  cells  expressing  HIV∆nefP2-Stop  and  HIV∆nefP3-
Stop were then used as targets to activate EM40-F21 (Fig. 5 D). 
Activation levels obtained with truncated P2 and P3 Gags 
were similar to or higher than those induced by cells produc-
ing infectious HIV (Fig. 5 D). CTL activation by infectious 
HIV, or by HIV-P2-Stop or -P3-Stop, was blocked by the 
proteasome inhibitor epoxomicin (Fig. 5 E), strongly suggest-
ing that processing of full-length and truncated Gag-derived 
epitopes  occurs  through  the  classical  MHC-I  presentation 
pathway. Therefore, defective HIV strains bearing premature 
STOP codons are efficiently recognized by HS-CTLs.
Concluding remarks
AID/APOBEC family members are cytidine deaminases that 
exert different functions in the host defense against pathogens. 
In B cells, AID is necessary for antibody somatic hypermuta-
tion and class-switch recombination. AID provides the molec-
ular flexibility that is crucial to establishing efficient humoral 
immune responses. APOBEC3 proteins offer a strong innate 
antiviral defense. Recent studies suggested that the adaptive 
and innate immune functions of APOBEC3/AID family 
members might overlap. AID protects the host against the 
oncogenic viruses Abelson murine leukemia virus, Epstein-
Barr virus, and hepatitis B virus (Rosenberg and Papavasiliou, 
2007). AID seems to act on the host genome through a mech-
anism that is not yet fully understood (Gourzi et al., 2007). 
Conversely, mouse APOBEC3 (mA3) is required to establish 
an efficient neutralizing antibody response against Friend virus 
(Santiago et al., 2008). Again the mechanism remains to be 
determined, however it has been proposed that mA3 might be 
involved in shaping the antibody repertoire. In the present 
study, we reveal a new role for A3G. In addition to restricting 
viral replication, A3G enhances the capacity of infected T cells 
to activate virus-specific CTLs. This phenomenon requires 
the editing activity of A3G.
Misfolded or truncated proteins represent a major source 
of peptides for the loading of MHC-I molecules (Yewdell 
and Nicchitta, 2006). This was demonstrated using several 
model antigens, such as influenza NP, OVA, or HIV-1 pro-
teins. For instance, targeting HIV-1 Gag/Nef and Env to 
rapid proteasomal degradation by the addition of N-terminal 
degron signals (i.e., Arginine residue and/or ubiquitin fusion 
Figure 4.  The editing activity of A3G is required to enhance HS-
CTL activation. (A) CEM-A2+ cells were infected with HIVNL∆nef produced 
without A3G or in the presence of WT and C-terminal domain mutants 
(H257R and C288S) of A3G (triangles, p24 doses: 20 and 10 ng/ml). 48 h 
after infection, viral infection was analyzed by Gagp24 staining (data are 
representative of four independent experiments) and infected cells were 
used to stimulate HS-CTL clone EM40-F21 in an IFN- Elispot (10,000 
clones/well) (B). Background IFN- production induced by uninfected cells 
has been subtracted. Background IFN- productions by CEM-A2+ cells 
alone were close to zero. Activation levels reached using SL9 peptide–
loaded cells as positive control were 600 IFN-+ spots/well (not de-
picted). (C) Data are presented as a ratio of IFN- Elispot to percentage of 
Gag+ cells. Impairing the editing activity of A3G abrogates A3G-mediated 
enhancement of CTL recognition. Data are the mean (±SD) of triplicates 
and are representative of four independent experiments.46 APOBEC3G promotes CTL activation | Casartelli et al.
Figure 5.  Defective viruses with premature STOP codons are efficiently recognized by HS-CTLs. (A) Schematic representation of the strategy 
used to construct defective HIV (HIVNL∆nefP2 and HIVNL∆nefP3) mimicking A3G-mediated editing. (Top) Nucleotide and amino acid sequences of a fraction  
of gag gene (gagP2) targeted for mutagenesis. The G-to-A transition introduced by mutagenesis is underlined and the resulting amino acid change (W212 
to STOP) is in bold. Nucleotide numbering is according to HIVLAI sequence. (Bottom) Schematic representation of Gag full length and truncated Gag pro-
teins (GagP2 and GagP3) generated by mutagenesis. The SL9 peptide amino acid sequence within p17 is indicated. HeLa-A2+ cells were transfected with 
HIV, HIVNL∆nefP2, and HIVNL∆nefP3 proviruses. (B and C) Gag expression profiles were analyzed 2 d after transfection using anti-p17 antibody and Western 
blotting (B) or anti-p24 antibody and FACS (C). Data are representative of three independent experiments. For Western blotting, transfected cells were 
pelleted, lyzed, loaded on SDS-PAGE, and transferred to nitrocellulose. Membranes were then incubated with antibodies to p17 and actine. (D) HeLa-A2+ 
cells were transfected with the indicated doses of provirus. At 36 h after transfection, cells were used to activate HS-CTL clone EM40-F21 in an IFN- 
Elispot assay (10,000 clones/well). Data are the mean (±SD) of triplicates and are representative of three independent experiments. (E) Hela-A2 cells  
transfected with 1 µg of indicated HIV DNA were mock or Epoxomicin treated (1 µM) for 6 h prior to co-culture with HS-CTLs. Epoxomicin, a proteasome 
inhibitor, diminishes CTL activation. Background IFN- production induced by untransfected cells is shown. Background IFN- productions by target cells 
alone have been subtracted and are at least three times lower than with HS-CTLs. Activation levels reached using SL9 peptide–loaded cells as positive 
control were 400 IFN-+ spots/well (not depicted). Data are mean (±SD) of triplicates and are representative of two independent experiments.JEM VOL. 207, January 18, 2010  47
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PQVPLR77)  and  CMV  (T10AM,  pp65  417TPRVTGGGAM426)  were 
derived  from  splenocytes  of  peptide-immunized  HLA-B7m3  transgenic 
mice (Cardinaud et al., 2004). Splenocytes were cultured in RPMI 1640 
supplemented with 10% fetal bovine serum and stimulated every 10 d with 
peptide-pulsed syngeneic LPS lymphoblasts.
Virus and infection
The HIV strains used in the study were HIVNL4-3, HIVSF2, and their ∆nef 
counterparts (Fackler et al., 2006). HIV and HIV(VSV) virions were pro-
duced and titrated as previously described (Moris et al., 2004). HIV virions 
containing A3G WT and H257R or C288S mutants were produced in 293T 
cells by cotransfection (1:1 DNA ratio) of HIV provirus with a pcDNA3-V5 
plasmid encoding for WT or mutant A3G (A3G and mutant constructs pro-
vided by A.J. Hance [Hopital Bichat, Paris, France] and M.H. Malim [King’s 
College, London, England, UK]). pNL4-3 XCS and pNL4-3∆vif XCS (pro-
vided by A.J. Hance) were used to generate HIVNL∆nef and HIVNL∆nefvif, re-
spectively. In brief within nef, a frame shift mutation of four bases was 
inserted at a unique XhoI site (Schwartz et al., 1996). HIVNL∆nefP2 and 
HIVNL∆nefP3 proviruses were generated by introducing in HIVNL∆nef a STOP 
codon at positions 212 and 249 (amino acid sequence), respectively, using 
the primers for HIVNL∆nefP2 (5-GAGGAAGCTGCAGAATAGGATAG-
ATTGCATCCAG-3) and HIVNL∆nefP3 (5-CAGGAACAAATAGGATA-
GATGACACATAATCCACCTATCC-3;  mutagenized  nucleotides  in 
bold) with QuikChange XL Site-Directed Mutagenesis kit (Stratagene). 48 h 
after transfection, viral supernatants were collected and p24 content was mea-
sured by ELISA (PerkinElmer). When stated, the infectivity was tested using 
HeLa-CD4+ cells (P4 cells), which carry the integrated HIV LTR-lacZ   
reporter cassette. P4 was infected with 5 ng p24 of the indicated viruses. 48 h 
later, -galactosidase activity was measured in cell extracts.
5  ×  106  CEM-A2+,  Hela-A2+,  HUT-A2+,  and  T1-B7  cells  were   
infected with various amount of HIV (ranging from 10 to 100 ng p24/ml) 
for 3 h at 37°C in 10 mM Hepes, pH 7.4, and 2 µg/ml DEAE-dextran con-
taining culture medium. Primary CD4+ T cells were PHA activated (1 µg/ml 
for 48 h; Abbot Laboratories), washed, and grown in IL-2–containing cul-
ture medium (50 IU/ml; Proleukin [Novartis]) for at least 10 d. Cells were 
then infected for 3 h at 37°C with 10–100 ng/ml HIV in the presence of 
DEAE-dextran and grown with IL-2. Viral replication was then followed 
using either p24 intracellular staining. Infected cells were then used as anti-
gen presenting cells in Elispot assays.
Flow cytometry
Cells were fixed, permeabilized, and stained using standard procedures with 
anti-Gagp24 (KC57; Beckman Coulter) or an IgG1 isotype mAb as a negative 
control. Samples were analyzed using FACSCalibur (BD).
T cell activation assays
Elispot. Stimulator cells were co-cultured for at least 8 h with CD8+ T cell 
clones (ranging from 2,500 to 104 EM40-F21/well and 2,000 to 104 anti-Nef 
CTLs/well). IFN- production was then measured in an Elispot assay as pre-
viously described (Moris et al., 2004). As positive controls, stimulators were 
incubated with 1 µg/ml of cognate (SL9) peptides before addition of CTLs.
Chemokine quantification by Luminex. Infected or SL9 peptide–loaded 
stimulator cells were co-cultured in a 96-well plate with EM40-F21 at a 1/50 
and 1/10 ratio (5,000 CTLs for 250,000 or 50,000 CD4+ T cells, respectively). 
Cell culture supernatants were collected after 24 h, and MIP-1 and MIP-1 
secretion was measured according the manufacturer’s instructions (Chemokine 
Human 5-plex Panel LHC0005; Invitrogen).
Western blots. 24 or 48 h after transfection, cells were lyzed in PBS-1% 
Triton  X-100  (Sigma-Aldrich)  supplemented  with  protease  inhibitors 
(Roche). Viral supernatants were ultracentrifuged (105 rpm for 20 min) and 
resuspended in PBS containing 1% triton and protease inhibitors. Cell lysates 
and viral particles were analyzed by SDS-gel electrophoresis using 4–12% 
NuPAGE  gels  (Invitrogen).  Anti-HIVp17,  anti-V5  (both  provided  by   
sequence)  resulted  in  enhanced  MHC-I  presentation  and   
increased activation of mouse CTLs (Tobery and Siliciano, 
1997; Goldwich et al., 2008). We extend these observations 
by showing that premature STOP codons in HIV genome, a 
hallmark of A3G editing, enhance CTL activation. We sug-
gest that truncated/misfolded HIV polypeptides, generated 
by A3G, supply the pool of MHC-I–restricted HIV antigens. 
In addition to A3G, other mechanisms (e.g., viral recombina-
tion or errors during reverse transcription) generate crippled 
viruses. These defective viruses might also be an underesti-
mated source of antigens.
HIV  has  developed  multiple  mechanisms  for  escaping 
CTLs. Nef, by modulating MHC-I expression, decreases the 
recognition and killing of infected cells by CTLs. The efficacy of 
Nef-mediated CTL escape is partial and depends on the kinetic 
of antigen expression and on the quantity of MHC-I–HIV 
epitope complexes (Fig. 1; Tomiyama et al., 2005). We show in 
this paper that A3G enhances the generation of HIV-derived 
epitopes,  thus  partially  counteracting  the  action  of  Nef. 
Moreover, in primary CD4+ T cells, Vif reduced the capacity 
of infected cells to activate CTLs by degrading A3G. Recog-
nition of HIV-infected cells by CTLs results from a balance 
between the efficacy of the generation of antigens enhanced 
by A3G editing and the immune-escape mechanisms mediated 
by Nef and Vif.
A3G has several genetic variants that might influence the 
progression to AIDS (An et al., 2004). It will be worth exam-
ining the contribution of A3G polymorphism in the induction 
of CTL responses. Simian immunodeficiency virus (SIV) might 
also be used to further characterize the role of A3G in CTL 
activation because Vif-deficient SIV replicates poorly but elic-
its an antibody response in macaques (Desrosiers et al., 1998).
In conclusion, cellular and viral factors determine the 
  efficiency of antigen presentation that, in turn, influences the 
quality of T cell responses and thus the control of HIV infec-
tion (Appay et al., 2008). Our study demonstrates that A3G-
mediated viral restriction contributes to the immunogenicity 
of HIV-infected cells and to CTL activation, thus linking   
innate and adaptive immunity. It is tempting to speculate that 
the function of A3G in enhancing CTL recognition occurs 
with other APOBEC3/AID family members and with other 
viruses sensitive to cytidine deamination.
MATERIALS AND METHODS
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PBMCs were isolated by ficoll density gradient from the blood of healthy 
donors and screened by FACS for the expression of HLA-A*02 using BB7.2 
antibody. CD4+ T lymphocytes were then isolated from PBMCs using neg-
ative depletion (Miltenyi Biotec). HeLa-CIITA-HLA-A*0201+ and HUT-
HLA-A*0201+ cell lines were generated by electroporation and selection 
using  G418.  CEM-HLA-A*0201+  cells  were  provided  by  K.L.  Collins 
(University of Michigan, Ann Arbor, MI). T1 (174xCEM, CCR5+ LTR-
GFP+) cells stably transfected with the HLA-B7m3 construct were used as 
antigen-presenting cells (Cardinaud et al., 2004).
The HS EM40-F21 CTL clone is specific for Gag p17 (aa 77–85) 
  presented by HLA-A*0201 and has been previously described (Moris et al., 
2004). Human protocols were approved by the ethics committee of the Pas-
teur Institute. CTL lines specific for the HIV Nef (F10LR, Nef 68FPVT-48 APOBEC3G promotes CTL activation | Casartelli et al.
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